Status:
COMPLETED
Study in COPD (Chronic Obstructive Pulmonary Disease) Subjects to Investigate Safety, Tolerability, and Pharmacokinetics of Ciprofloxacin After Single Dose Inhalations of 50 mg and 75 mg Ciprofloxacin Inhalation Powder
Lead Sponsor:
Bayer
Conditions:
Infection
Pulmonary Disease, Chronic Obstructive
Eligibility:
All Genders
40-75 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to compare the safety and pharmacokinetics of ciprofloxacin after inhalation of single 52.5 and 48.75 mg doses in COPD patients. In this study the 48.75 mg dose will be ad...
Eligibility Criteria
Inclusion
- Adult subjects with COPD, 40 - 75 years of age
- All subjects must have a diagnosis of COPD and must have airway obstruction with a post-bronchodilator Forced Expiratory Volume in 1 sec (FEV1) of \>/= 30% and \<= 80% of predicted and a post-bronchodilator FEV1 / Forced Vital Capacity (FVC) of \</= 70%
- Subjects must be current or ex-smokers with a smoking history of more than 10 pack-years
- Subjects must be able to perform technically acceptable pulmonary function tests during the study period as required in the protocol
- Subjects must be able to produce an sufficient amount of sputum during sputum induction at screening
Exclusion
- Subjects with a significant respiratory disease other than COPD.
- Exacerbation within 8 weeks prior to screening
- Subjects with more than 1 COPD exacerbation within 12 months prior to screening
- Subjects must have an FEV1 of at least one Liter
- Subjects with a history or physician's diagnosis of asthma. If a patient has a total blood eosinophil count \>/= 0.6 x 10\^9/L source documentation is required to verify that the increased eosinophil count is related to a non-asthmatic condition.
- Subjects with hypersensitivity to the ciprofloxacin or to other quinolones and/or to inactive constituents of the inhalation powder
- Subjects with known hypersensitivity of the bronchial system to inhalation of nebulized drugs or saline solution
- Subjects with a history of cystic fibrosis
- Subjects with clinically evident bronchiectasis
- Subjects taking any:
- Oral beta-adrenergic drugs or non cardioselective beta blockers,
- Oral glucocorticoids,
- Antihistamines or antileukotrienes prescribed for asthma,
- Oral cromolyn sodium or oral nedocromil sodium,
- Concomitant inhalative therapy with antibiotics and / or concomitant systemic therapy with fluoroquinolones
Key Trial Info
Start Date :
July 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2010
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT01168895
Start Date
July 1 2010
End Date
September 1 2010
Last Update
April 14 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Großhansdorf, Schleswig-Holstein, Germany, 22927